TScan Therapeutics (TCRX) FCF Margin (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly FCF Margin of 2479.53% for Q1 2026, down 67769.0% year-over-year from N/an in Q1 2025, and down 99.17% quarter-over-quarter from 1244.92% in Q4 2025.
TScan Therapeutics (TCRX) FCF Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported FCF Margin for 7 consecutive years, with 2479.53% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin fell 67769.0% year-over-year to 2479.53%; the TTM figure through Mar 2026 stood at 1319.58% (up 148053.0% YoY), while the FY2025 annual figure was 1310.66%, up 276061.0% from the prior year.
- FCF Margin eased to 2479.53% in Q1 2026 per TCRX's latest filing, from 1244.92% in the prior quarter.
- Across five years, FCF Margin topped out at 199.67% in Q3 2023 and bottomed at 5295.41% in Q1 2024.
- Historically, FCF Margin has averaged 1676.72% across 5 years, with a median of 1061.87% in 2025.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 488832 bps — and 2025, when it soared 399168 bps.
- TScan Therapeutics' FCF Margin stood at 513.15% in 2022, then soared by 36 bps to 329.0% in 2023, then sank by 1194 bps to 4255.64% in 2024, then soared by 71 bps to 1244.92% in 2025, then slumped by 99 bps to 2479.53% in 2026.
- Business Quant data shows TCRX's FCF Margin at 2479.53% in Q1 2026, 1244.92% in Q4 2025, and 1257.98% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | TScan Therapeutics | 101.63 Mn | 101.63 Mn | - | -2,666.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,666.79% |
| Mar 31, 2026 | -2,479.53% |
| Dec 31, 2025 | -1,244.92% |
| Sep 30, 2025 | -1,257.98% |
| Jun 30, 2025 | -1,061.87% |
| Mar 31, 2025 | -1,801.84% |
| Dec 31, 2024 | -4,255.64% |
| Sep 30, 2024 | -2,791.99% |
| Jun 30, 2024 | -5,053.54% |
| Mar 31, 2024 | -5,295.41% |
| Dec 31, 2023 | -329.00% |
| Sep 30, 2023 | 199.67% |
| Jun 30, 2023 | -701.56% |
| Mar 31, 2023 | -407.09% |
| Dec 31, 2022 | -513.15% |
| Sep 30, 2022 | -450.49% |
| Jun 30, 2022 | -376.23% |
| Mar 31, 2022 | -683.71% |
| Dec 31, 2021 | -581.32% |
| Sep 30, 2021 | -870.27% |